The Intra- Cellular Therapies is a biopharmaceutical company. It is also known as ICTI. The main focus of this company on the discovery and clinical development of innovation. This discovery is made for neuropsychiatric and neurological disorders with the central Nervous system. The lead product is ITI-007 and it’s the first-class treatment for Schizophrenia.
The main work of Intra- Cellular Therapies, Inc. (NASDAQ: ITCI) main focused on biopharmaceutical development